[go: up one dir, main page]

PL1896507T3 - Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych - Google Patents

Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych

Info

Publication number
PL1896507T3
PL1896507T3 PL06795343T PL06795343T PL1896507T3 PL 1896507 T3 PL1896507 T3 PL 1896507T3 PL 06795343 T PL06795343 T PL 06795343T PL 06795343 T PL06795343 T PL 06795343T PL 1896507 T3 PL1896507 T3 PL 1896507T3
Authority
PL
Poland
Prior art keywords
monoclonal antibodies
malignant tumour
tumour cells
treating malignant
cells
Prior art date
Application number
PL06795343T
Other languages
English (en)
Inventor
Laurence Boumsell
Jean Kadouche
Armand Bensussan
Original Assignee
Inst Nat Sante Rech Med
Monoclonal Antibodies Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Monoclonal Antibodies Therapeutics filed Critical Inst Nat Sante Rech Med
Publication of PL1896507T3 publication Critical patent/PL1896507T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL06795343T 2005-06-15 2006-06-14 Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych PL1896507T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/154,262 US7736647B2 (en) 2005-06-15 2005-06-15 Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
PCT/IB2006/002331 WO2007000671A2 (en) 2005-06-15 2006-06-14 Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells
EP06795343A EP1896507B1 (en) 2005-06-15 2006-06-14 Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells

Publications (1)

Publication Number Publication Date
PL1896507T3 true PL1896507T3 (pl) 2010-08-31

Family

ID=37573538

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06795343T PL1896507T3 (pl) 2005-06-15 2006-06-14 Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych

Country Status (10)

Country Link
US (2) US7736647B2 (pl)
EP (1) EP1896507B1 (pl)
JP (1) JP5185815B2 (pl)
AT (1) ATE459653T1 (pl)
CA (1) CA2612486A1 (pl)
DE (1) DE602006012672D1 (pl)
DK (1) DK1896507T3 (pl)
ES (1) ES2341625T3 (pl)
PL (1) PL1896507T3 (pl)
WO (1) WO2007000671A2 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003601A (es) * 2008-10-23 2011-04-27 Hoffmann La Roche Determinacion de acido nucleico que codifica inmunoglobulina.
CN104710504B (zh) 2009-07-22 2019-09-13 锕医药股份有限公司 用于制备放射性免疫缀合物的方法
WO2011130164A2 (en) * 2010-04-13 2011-10-20 The Regents Of The University Of California Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
DK2646470T3 (en) 2010-11-30 2017-05-08 Hoffmann La Roche ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
JP2014518615A (ja) * 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル, エルエルシー 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
EA201700111A1 (ru) 2011-10-28 2018-02-28 Тева Фармасьютикал Австралия Пти Лтд Полипептидные конструкции и их применение
ES2992753T3 (en) 2012-08-24 2024-12-17 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
BR112017023868A2 (pt) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
US10179817B2 (en) 2015-05-04 2019-01-15 Cytomx Therapeutics, Inc. Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
EP3325006A4 (en) 2015-07-17 2019-03-06 The Trustees of Columbia University in the City of New York METHOD FOR TREATING CD166-EXPRESSIVE CANCER
EA201890613A1 (ru) 2015-09-21 2018-10-31 Аптево Рисёрч Энд Девелопмент Ллс Полипептиды, связывающие cd3
UA125898C2 (uk) 2016-03-04 2022-07-06 Джн Байосайєнсіз, Ллк Антитіла до tigit
MA45328A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
EP3473270B1 (en) 2016-06-20 2022-11-30 Genahead Bio, Inc. Antibody-drug conjugate
IL299099B1 (en) 2016-06-27 2025-03-01 Univ California Combinations of cancer treatments
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
JP7573966B2 (ja) 2017-01-06 2024-10-28 アビディティー バイオサイエンシーズ,インク. エクソンスキッピングを誘導する核酸ポリペプチド組成物および方法
US20180303952A1 (en) 2017-03-09 2018-10-25 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
KR102258014B1 (ko) * 2019-05-15 2021-05-27 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
KR102258015B1 (ko) * 2019-05-15 2021-05-27 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
CN114127117B (zh) * 2019-07-19 2024-03-15 上海药明合联生物技术有限公司 用于偶联的多肽复合物及其应用
JP2022548310A (ja) 2019-09-23 2022-11-17 シートムエックス セラピューティクス,インコーポレイテッド 抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
IL298111A (en) 2020-06-02 2023-01-01 Arcus Biosciences Inc Antibodies to tigit
EP4323409A4 (en) 2021-04-14 2025-04-16 Aro Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
CA3215367A1 (en) 2021-04-14 2022-10-20 Swapnil Kulkarni Fn3 domain-sirna conjugates and uses thereof
EP4396231A1 (en) 2021-09-01 2024-07-10 Biogen MA Inc. Anti-transferrin receptor antibodies and uses thereof
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308626A (en) 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
CA2081368A1 (en) 1990-03-27 1991-09-28 Ian S. Trowbridge Method for inhibiting cell growth and compositions useful therefor
US5762932A (en) * 1990-04-26 1998-06-09 University Of Iowa Research Foundation Combined treatment of iron depletion and IgG antibody
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
KR101295139B1 (ko) 2004-06-07 2013-08-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 트랜스페린 리셉터 항체

Also Published As

Publication number Publication date
JP5185815B2 (ja) 2013-04-17
DK1896507T3 (da) 2010-06-07
JP2009509497A (ja) 2009-03-12
US20110311544A1 (en) 2011-12-22
EP1896507A2 (en) 2008-03-12
US20060286030A1 (en) 2006-12-21
US7736647B2 (en) 2010-06-15
DE602006012672D1 (de) 2010-04-15
ATE459653T1 (de) 2010-03-15
US8409573B2 (en) 2013-04-02
WO2007000671A3 (en) 2007-04-26
CA2612486A1 (en) 2007-01-04
EP1896507B1 (en) 2010-03-03
ES2341625T3 (es) 2010-06-23
WO2007000671A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
PL1896507T3 (pl) Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych
SG171690A1 (en) Treatment of protein degradation disorders
TW200740844A (en) Novel MAdCAM antibodies
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
UA94707C2 (en) Antigen-binding molecule capable of binding to plgf
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
MX2020011789A (es) Anticuerpos monoclonales contra claudina-18 para el tratamiento de cancer.
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2004058705A3 (en) Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor
TW200738236A (en) Certain chemical entities, compositions, and methods
TW200621260A (en) Selected fused heterocyclics and uses thereof
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
PL1776103T3 (pl) Kompleksy rutenu do leczenia raków
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13
TW200621270A (en) Novel use of nanogold for manufacturing medicaments for inhibiting metastasis of malignant tumors and growth of leukemic cells, and pharmaceutical compositions for inhibiting metastasis of malignant tumors and for treating leukemia comprising nanogold
UA93875C2 (ru) Выделенное химерическое или гуманизированное антитело, kotopoe специфически связывается c полипептидом tat10772 (ca125)
TW200504026A (en) N-aryl-heteroaromatic products, compositions containing them and use thereof
WO2006125139A3 (en) Therapeutic uses of kallikreins